Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33926916.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0729.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Similar risk reduction but fewer side effects would predict more uptake and compliance with low (5 mg) versus full (20 mg) dose tamoxifen. Benefit with low dose is demonstrated for perimenopausal/postmenopausal women with intraepithelial neoplasia and high lesion Ki-67. Longer follow-up needed to determine benefit with low lesion Ki-67.<i>See related article by DeCensi et al., p. 3576</i>.
Medical subject headings
- Breast Diseases
- Carcinoma in Situ
- Precancerous Conditions